Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) EBT Margin (2023 - 2025)

Historic EBT Margin for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to 2623.53%.

  • CG Oncology's EBT Margin rose 448253100.0% to 2623.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 6963.71%, marking a year-over-year increase of 36779600.0%. This contributed to the annual value of 7729.76% for FY2024, which is 160668100.0% up from last year.
  • Latest data reveals that CG Oncology reported EBT Margin of 2623.53% as of Q3 2025, which was up 448253100.0% from 66263.46% recorded in Q1 2025.
  • Over the past 5 years, CG Oncology's EBT Margin peaked at 2623.53% during Q3 2025, and registered a low of 1655100.0% during Q4 2023.
  • Moreover, its 3-year median value for EBT Margin was 17036.04% (2024), whereas its average is 214864.91%.
  • As far as peak fluctuations go, CG Oncology's EBT Margin skyrocketed by 2000000000bps in 2024, and later plummeted by -630640300bps in 2025.
  • CG Oncology's EBT Margin (Quarter) stood at 1655100.0% in 2023, then skyrocketed by 100bps to 6974.56% in 2024, then surged by 62bps to 2623.53% in 2025.
  • Its last three reported values are 2623.53% in Q3 2025, 66263.46% for Q1 2025, and 6974.56% during Q4 2024.